Ocuphire Pharma
two treatment options for spectrum of presbyopic patients pursuing product labels for drop and drop options for the treatment of presbyopia initiating phase program in mid for both labels mid art dian | Ocuphire Pharma
Company
Deck Type
Deck date
January 2022
Slide
97 of 114
Related slides by other companies
BioAtla
Investor Presentation
January 2024
cab phase mono and study currently underway | BioAtla
NeuroSense Therapeutics
Investor Presentation
December 2023
focused pipeline | NeuroSense Therapeutics
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights